Cardiovascular Diseases Clinical Trial
Official title:
Effects of Gender-Affirming Hormone Therapy Among Transgender Women
Verified date | February 2024 |
Source | Massachusetts General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In this study, investigators plan to evaluate the cardiometabolic effects of initiating gender-affirming hormone therapy among transgender women with and without HIV. As part of this study, participants will undergo cardiovascular and metabolic phenotyping within 3 months of starting and after 12 months of gender-affirming hormone therapy. Cardiovascular phenotyping will include cardiac MRI/MRS imaging to evaluate cardiac function and structure. Metabolic phenotyping will include oral glucose tolerance testing, abdominal MR imaging to evaluate visceral adiposity, and whole body, lumbar, and hip DEXA imaging to evaluate fat and lean body mass as well as bone mineral density, respectively. Traditional markers of CVD risk as well as immune, hormonal, and coagulation parameters will also be assessed longitudinally.
Status | Active, not recruiting |
Enrollment | 33 |
Est. completion date | November 1, 2024 |
Est. primary completion date | November 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 16 Years to 99 Years |
Eligibility | Inclusion Criteria: - transgender women or non-binary individual - age =16 - For women with HIV only: on ART therapy for =3 months - initiation of testosterone suppression with spironolactone or leuprolide and estrogen therapy with oral 17-ß estradiol, transdermal 17ß estradiol, sublingual estradiol, intramuscular estradiol, or subcutaneous estradiol by medical provider Exclusion Criteria: - For women with HIV only: CD4 count<50 - history of CAD, ACS, ASCVD risk score = 7.5%, LDL-C = 190, or angina (e.g. current indication for statin use) - history of heart failure - history of diabetes - eGFR < 30 ml/min/1.73m2 - standard contraindication to MRI, including history of severe allergy to gadolinium or Dotarem - prior orchiectomy - gender-affirming hormone therapy for greater than 5 months directly prior to enrollment - current or past anti-platelet therapy or anti-coagulant therapy within the last 6 months •current or past statin therapy within the last 6 months - concurrent enrollment in conflicting research study |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital | American Heart Association, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Robert Wood Johnson Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Visceral Adipose Tissue | Baseline and 12 months | ||
Secondary | Change in Intramyocardial Triglyceride Content on Cardiac MRS | Baseline and 12 months | ||
Secondary | Change in Diastolic Function on Cardiac MRI | Baseline and 12 months | ||
Secondary | Change in Myocardial Fibrosis on Cardiac MRI | Baseline and 12 months | ||
Secondary | Change in Glucose and Insulin Parameters on Oral Glucose Tolerance Testing | Baseline and 12 months | ||
Secondary | Change in Bone Density | Baseline and 12 months | ||
Secondary | Change in Hormonal Parameters | Baseline and 12 months | ||
Secondary | Change in Coagulation Parameters | Baseline and 12 months | ||
Secondary | Change in hepatic lipid content | Baseline and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|